• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 01, 2018 at 09:42: PM
via AbbVie (NYSE: ABBV), announced on 5/1/18 that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.

article source
 




Top Bottom
Back
Quote